Sciatica - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2024 - 2029

The Sciatica market is projected to register a CAGR of 9.5% during the forecast period.

The COVID-19 pandemic had a significant impact on the sciatica market. A study published in the Journal of Pain Research in June 2021 showed that after hospital discharge, 27.3% of post-COVID-19 individuals reported joint pain and 21.7% chest pain. Again, it was highlighted that four weeks after discharge from the hospital, 10-20% of patients treated in the ward suffered from myalgia and the percentage increased to up to 30% in those who needed ICU hospitalization. Hence, with such studies, it was observed that there was a growing prevalence of pain during the pandemic which positively impacted the market studied. However, the market studied has reached its pre-pandemic nature currently and is expected to witness strong growth in the coming years.

Certain factors that are driving the market growth include the high recurrence rate of sciatica patients, which proves to be positive upfront for the sciatica market and helps patients to try new interventions. Sciatica is likely to recur if the spinal disc that contributed to Sciatica is severely damaged. The more damaged the disc, the more likely it is to re-herniate and causes Sciatica again.

In a study published in the National Library of Medicine in August 2022, patients with chronic pain (more than six months) had a poorer outcome following surgery than patients with acute pain (less than six months). Some studies reported a cure rate of more than 75%, but other studies report cure rates of less than 50%. There are several newer orthopedic procedures to manage Sciatica, and these procedures have success rates of 70% and above in the short term. Therefore, with the advances in orthopedic procedures, the market studied is believed to grow in the coming years.

Several environmental and inherent factors thought to influence the development of Sciatica have been studied, including gender, body habitus, parity, age, genetic factors, occupation, and environmental factors. For instance, according to Mayo Clinic data published in January 2021, it was estimated that in the United States, 80% of the population will have low back pain in their lifetime. Thus, the increasing burden of Sciatica is leading to increasing demand for its treatment, as it is one of the most common conditions leading to chronic pain, thereby contributing to market growth.

However, the lack of proper diagnostic tests and the availability of off-label medication are some of the factors restraining the market growth.

Sciatica Market Trends

The Non-Steroidal Anti Inflammatory Drug Segment is Expected to Witness a Strong Growth

The main antiinflammatory, antipyretic, and analgesic effect of NSAIDs is based on the suppression of the cyclooxygenase (COX)1 and COX2 enzymes. By blocking the COX enzymes, vasodilation is reduced and inflammation relieved. Non-steroidal antiinflammatory drugs (NSAIDs) are one of the most frequently prescribed drugs for the treatment of sciatica. The products are getting approvals and hence, creating lucrative opportunities in the market. As per sciaticapain.co.uk, 2022, painkillers stop the production of these cells, and the brain stops signaling that there is pain somewhere in the body.

Pain killers and anti-inflammatory medicines are the most effective medicines that make up the most numerous group of drugs. Most commonly, antirheumatics (painkillers) are used to treat pain, fever, muscle pain, and other musculoskeletal disorders. Doctors recommend low-dose medications that can be purchased over the counter, such as Ibuprofen or Tylenol. The over-the-counter NSAIDs are meant to provide pain relief. Prescription NSAIDs may be necessary for pain relief if over-the-counter drugs are ineffective. Therefore, with the significance of NSAIDs in coping with sciatica, the segment is expected to grow significantly in the forecast period.

North America is Expected to Hold a Significant Share in the Market

North America is expected to hold a major market share in the global Sciatica market due to the rise in the geriatric population and the increasing prevalence of lower back pain in this region. As per a study published by National Center for Health Statistics, in 2021, around 39% of adults in the United States stated they had experienced back pain within the past three months. A greater number of orthopedic procedures due to greater healthcare penetration in the United States and Canada drives the sciatica market.

Further, the increasing geriatric population of the region is expected to have a significant impact on the growth of the studied market as the older population is more prone to pain and other musculoskeletal disorders. For instance, according to the 2021 report of the United States Census Bureau, more than 54 million people of age 65 years and above were living in the country during 2021 and this number is projected to reach 85.7 million by 2050, which will be about 20% of the total population of the United States. As old people are prone to develop sciatica, the market studied is expected to grow as a result of the geriatric population increase.

Moreover, high expenditure on healthcare, especially in the United States and Canada, along with increased awareness about the disease, are fueling the growth of the overall regional market to a large extent. Therefore, due to the aforementioned factors, the North American region is expected to hold a significant share of the sciatica market over the forecast period.

Sciatica Industry Overview

The Sciatica market is fragmented, competitive in nature, and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Sorrento Therapeutics, SpineThera, Eliem Therapeutics, Scilex Holding, Sinfonia Biotherapeutics, Seikagaku Corporation, Kolon life Science and others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support